STOCK TITAN

Endra Life Sciences Inc Stock Price, News & Analysis

NDRA Nasdaq

Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.

ENDRA Life Sciences Inc. (NDRA) is an imaging technology company developing the Thermo Acoustic Enhanced UltraSound (TAEUS®) platform, with a primary focus on liver fat quantification for steatotic liver disease (SLD) and metabolic dysfunction‑associated steatohepatitis (MASH). News about ENDRA frequently centers on clinical data, regulatory planning and strategic shifts that affect how its technology may be used in metabolic disease management and drug development.

Recent press releases highlight feasibility and pilot study results in which ENDRA’s thermo‑acoustic fat fraction (TAFF) measurements are compared with MRI‑PDFF, the recognized imaging gold standard for liver fat. These updates provide details on statistical agreement across the SLD spectrum, performance at clinically important liver fat thresholds, and the implications for patient stratification and monitoring in MASLD/MASH and GLP‑1 trials. Investors and clinicians can follow how enhancements to TAEUS Liver’s probe design and algorithms are expected to improve accuracy and repeatability ahead of a planned De Novo pivotal study.

ENDRA news also covers its evolving go‑to‑market strategy, including a pivot toward metabolic disease and GLP‑1 therapy management, identification of key customer segments such as pharmaceutical companies, CROs and metabolic clinics, and plans for a subscription‑based access model. In parallel, the company issues updates on its digital asset treasury (DAT) strategy, including private placements, HYPE token purchases, and staking initiatives managed by Arca Investment Management with custody by Anchorage Digital Bank.

By following NDRA news on this page, readers can track clinical milestones, regulatory interactions, capital markets activity, and developments in ENDRA’s DAT program, all of which shape the company’s trajectory in both medical imaging and digital asset management.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.82%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
none

FAQ

What is the current stock price of Endra Life Sciences (NDRA)?

The current stock price of Endra Life Sciences (NDRA) is $3.36 as of March 6, 2026.

What is the market cap of Endra Life Sciences (NDRA)?

The market cap of Endra Life Sciences (NDRA) is approximately 4.0M.

NDRA Rankings

NDRA Stock Data

4.00M
627.50k
Diagnostics & Research
Electromedical & Electrotherapeutic Apparatus
Link
United States
ANN ARBOR

NDRA RSS Feed